On the contrary, nanoparticles are made for targeted delivery of sorafenib to the tumor; for example, medium-chain triglycerides and lactobionic acid-human serum albumin conjugate (LA-HSA conjugate) are used to create sorafenib-loaded albumin lipid nanoparticles (ALNs) as a targeted drug delivery system to treat hepatocellular carcinoma (HCC) [19]. The gene discussed is ALB; the disease is hepatocellular carcinoma.